For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Rimegepant - Migraine (prevention)
PAD Profile : Rimegepant - Migraine (prevention) Important
Traffic Light Status
Status 1 of 1.
- Oral lyophilisates
Guidelines
No guidelines returned.
Other Drugs
- Botulinum toxin type A
- Flunarizine dihydrochloride
- Pizotifen malate
- Erenumab
- Galcanezumab
- Fremanezumab
- Propranolol hydrochloride
- Topiramate
- Amitriptyline hydrochloride
- Gabapentin
- Pregabalin
- Candesartan cilexetil
- Clonidine hydrochloride
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves rimegepant in line with the recommendations made in NICE TA906, for preventing migraine.
Rimegepant for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians).
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.